Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma.
Rasi
G
G
Istituto di Medicina Sperimentale, Consiglio Nazionale Ricerche, Rome, Italy. guidorasi@hotmail.com
Terzoli
E
E
Izzo
F
F
Pierimarchi
P
P
Ranuzzi
M
M
Sinibaldi-Vallebona
P
P
Tuthill
C
C
Garaci
E
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins; D012449:Safety; D016019:Survival Analysis; D000077596:Thymalfasin; D013947:Thymosin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013947:Thymosin; D003606:Dacarbazine; D000077596:Thymalfasin